Vicapsys Life Sciences, Inc. (VICP): R&D Expense
Not updated since 2023-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$15.3K
Year ended 2023-12-31
-46.9%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2023-12-31 | $15.3K | +16.6% | 2024-10-21, From 2023-01-01 |
| 2022-12-31 | $13.1K | -26.0% | 2024-10-21, From 2022-01-01 |
| 2021-12-31 | $17.7K | -82.7% | 2023-04-14, From 2021-01-01 |
| 2020-12-31 | $102.2K | +3.2% | 2022-03-16, From 2020-01-01 |
| 2019-12-31 | $99.0K | n/a | 2021-09-17, From 2019-01-01 |